159 related articles for article (PubMed ID: 24723227)
1. Curcumin analogue UBS109 prevents bone loss in breast cancer bone metastasis mouse model: involvement in osteoblastogenesis and osteoclastogenesis.
Yamaguchi M; Zhu S; Zhang S; Wu D; Moore TM; Snyder JP; Shoji M
Cell Tissue Res; 2014 Jul; 357(1):245-52. PubMed ID: 24723227
[TBL] [Abstract][Full Text] [Related]
2. Curcumin analog UBS109 prevents bone marrow osteoblastogenesis and osteoclastogenesis disordered by coculture with breast cancer MDA-MB-231 bone metastatic cells in vitro.
Yamaguchi M; Zhu S; Weitzmann MN; Snyder JP; Shoji M
Mol Cell Biochem; 2015 Mar; 401(1-2):1-10. PubMed ID: 25416449
[TBL] [Abstract][Full Text] [Related]
3. Novel curcumin analogue UBS109 potently stimulates osteoblastogenesis and suppresses osteoclastogenesis: involvement in Smad activation and NF-κB inhibition.
Yamaguchi M; Moore TW; Sun A; Snyder JP; Shoji M
Integr Biol (Camb); 2012 Aug; 4(8):905-13. PubMed ID: 22751853
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
[TBL] [Abstract][Full Text] [Related]
5. Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis.
Zhang Z; Yao Y; Yuan Q; Lu C; Zhang X; Yuan J; Hou K; Zhang C; Du Z; Gao X; Chen X
Theranostics; 2020; 10(9):4042-4055. PubMed ID: 32226538
[No Abstract] [Full Text] [Related]
6. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling.
Sung B; Oyajobi B; Aggarwal BB
Mol Cancer Ther; 2012 Feb; 11(2):350-9. PubMed ID: 22090419
[TBL] [Abstract][Full Text] [Related]
7. Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.
Jun AY; Kim HJ; Park KK; Son KH; Lee DH; Woo MH; Chung WY
Invest New Drugs; 2014 Feb; 32(1):1-13. PubMed ID: 23673814
[TBL] [Abstract][Full Text] [Related]
8. Gentian violet inhibits MDA-MB-231 human breast cancer cell proliferation, and reverses the stimulation of osteoclastogenesis and suppression of osteoblast activity induced by cancer cells.
Yamaguchi M; Vikulina T; Weitzmann MN
Oncol Rep; 2015 Oct; 34(4):2156-62. PubMed ID: 26260090
[TBL] [Abstract][Full Text] [Related]
9. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of breast cancer metastasis to the lungs with UBS109.
Shoji M; Qian WP; Nagaraju GP; Brat DJ; Pessolano D; Luzietti R; Chennamadhavuni S; Yamaguchi M; Yang L; Liotta DC
Oncotarget; 2018 Nov; 9(90):36102-36109. PubMed ID: 30546830
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer.
Nagaraju GP; Zhu S; Ko JE; Ashritha N; Kandimalla R; Snyder JP; Shoji M; El-Rayes BF
Cancer Lett; 2015 Feb; 357(2):557-65. PubMed ID: 25497868
[TBL] [Abstract][Full Text] [Related]
12. Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption.
Strube A; Hoffmann J; Stepina E; Hauff P; Klar U; Käkönen SM
Clin Cancer Res; 2009 Jun; 15(11):3751-9. PubMed ID: 19470728
[TBL] [Abstract][Full Text] [Related]
13. The flavonoid p-hydroxycinnamic acid mediates anticancer effects on MDA-MB-231 human breast cancer cells in vitro: Implications for suppression of bone metastases.
Yamaguchi M; Murata T; Shoji M; Weitzmann MN
Int J Oncol; 2015 Oct; 47(4):1563-71. PubMed ID: 26238204
[TBL] [Abstract][Full Text] [Related]
14. Transcutaneous carbon dioxide application suppresses bone destruction caused by breast cancer metastasis.
Takemori T; Kawamoto T; Ueha T; Toda M; Morishita M; Kamata E; Fukase N; Hara H; Fujiwara S; Niikura T; Kuroda R; Akisue T
Oncol Rep; 2018 Oct; 40(4):2079-2087. PubMed ID: 30066936
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid hormone-related protein and bone metastases.
Guise TA
Cancer; 1997 Oct; 80(8 Suppl):1572-80. PubMed ID: 9362424
[TBL] [Abstract][Full Text] [Related]
16. The inhibitory effect of roasted licorice extract on human metastatic breast cancer cell-induced bone destruction.
Lee SK; Park KK; Park JH; Lim SS; Chung WY
Phytother Res; 2013 Dec; 27(12):1776-83. PubMed ID: 23401151
[TBL] [Abstract][Full Text] [Related]
17. Betulinic acid, a bioactive pentacyclic triterpenoid, inhibits skeletal-related events induced by breast cancer bone metastases and treatment.
Park SY; Kim HJ; Kim KR; Lee SK; Lee CK; Park KK; Chung WY
Toxicol Appl Pharmacol; 2014 Mar; 275(2):152-62. PubMed ID: 24463094
[TBL] [Abstract][Full Text] [Related]
18. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment.
Kang J; Choi YJ; Seo BY; Jo U; Park SI; Kim YH; Park KH
Sci Rep; 2019 Jun; 9(1):8726. PubMed ID: 31217507
[TBL] [Abstract][Full Text] [Related]
19. The botanical molecule p-hydroxycinnamic acid as a new osteogenic agent: insight into the treatment of cancer bone metastases.
Yamaguchi M
Mol Cell Biochem; 2016 Oct; 421(1-2):193-203. PubMed ID: 27573001
[TBL] [Abstract][Full Text] [Related]
20. Estradiol enhances osteolytic lesions in mice inoculated with human estrogen receptor-negative MDA-231 breast cancer cells in vivo.
Winding B; Misander H; Høegh-Andersen P; Brünner N; Foged NT
Breast Cancer Res Treat; 2003 Mar; 78(2):205-16. PubMed ID: 12725420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
